tiprankstipranks
Kazia Therapeutics Limited (KZIA)
NASDAQ:KZIA

Kazia Therapeutics Stock Analysis & Ratings

KZIA Stock Chart & Stats

Day’s Range$5.36 - $5.72
52-Week Range$5.01 - $12.28
Previous Close$5.23
Volume37.33K
Average Volume (3M)16.77K
Market Cap$75.92M
P/E Ratio-6.7
Beta2.39
Next EarningsSep 01, 2022
Dividend YieldN/A
Smart Score4
EPS (TTM)-0.84


Kazia Therapeutics News

Currently, no data available
Please return soon. This page is being updated.

---

Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

KZIA FAQ

What was Kazia Therapeutics’s price range in the past 12 months?
Kazia Therapeutics lowest stock price was $5.01 and its highest was $12.28 in the past 12 months.
    What is Kazia Therapeutics’s market cap?
    Kazia Therapeutics’s market cap is $75.92M.
      What is Kazia Therapeutics’s price target?
      The average price target for Kazia Therapeutics is $16.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $16.00 ,the lowest forecast is $16.00. The average price target represents 182.19% Increase from the current price of $5.67.
        What do analysts say about Kazia Therapeutics?
        Kazia Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Kazia Therapeutics’s upcoming earnings report date?
          Kazia Therapeutics’s upcoming earnings report date is Sep 01, 2022 which is in 106 days.
            How were Kazia Therapeutics’s earnings last quarter?
            Kazia Therapeutics released its earnings results on Feb 23, 2022. The company reported -$0.714 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.714.
              Is Kazia Therapeutics overvalued?
              According to Wall Street analysts Kazia Therapeutics’s price is currently Undervalued.
                Does Kazia Therapeutics pay dividends?
                Kazia Therapeutics pays a Notavailable dividend of $15.65 which represents an annual dividend yield of N/A. Kazia Therapeutics’s last Notavailable dividend payment was on Jan 25, 2013. Kazia Therapeutics’s upcoming ex-dividend date is Jan 28, 2013
                  What is Kazia Therapeutics’s EPS estimate?
                  Kazia Therapeutics’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does Kazia Therapeutics have?
                  Kazia Therapeutics has 13,390,000 shares outstanding.
                    What happened to Kazia Therapeutics’s price movement after its last earnings report?
                    Kazia Therapeutics reported an EPS of -$0.714 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.12%.
                      Which hedge fund is a major shareholder of Kazia Therapeutics?
                      Currently, no hedge funds are holding shares in KZIA

                      ---

                      Kazia Therapeutics Stock Analysis

                      The Kazia Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Kazia Therapeutics Limited

                      Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Roche Holding
                      Gilead Sciences
                      IQVIA Holdings
                      Immutep
                      Spectrum Pharmaceuticals

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis